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In embryonic stem cell culture, small molecules can be used to alter key signaling pathways to promote self-renewal
and inhibit differentiation. In mice, small-molecule inhibition of both the FGF/MEK/Erk and the GSK3b pathways
during preimplantation development suppresses hypoblast formation, and this results in more pluripotent cells of
the inner cell mass (ICM). In this study, we evaluated the effects of different small-molecule inhibitors of the FGF/
MEK/Erk andGSK3bpathwayon embryo preimplantation development, early lineage segregation, and subsequent
embryonic stem cell derivation in the humans. We did not observe any effect on blastocyst formation, but small-
molecule inhibition did affect the number of OCT3/4- andNANOG-positive cells in the human ICM.We found that
combined inhibition of the FGF/MEK/Erk and GSK3b pathways by PD0325901 and CHIR99021, respectively,
resulted in ICMs containing significantly more OCT3/4-positive cells. Inhibition of FGF/MEK/Erk alone as well as
in combination with inhibition of GSK3b significantly increased the number of NANOG-positive cells in blastocysts
possessing good-quality ICMs. Secondly, we verified the influence of this increased pluripotency after 2i culture on
the efficiency of stem cell derivation. Similar human embryonic stem cell (hESC) derivation rateswere observed after
2i compared to control conditions, resulting in 2 control hESC lines and 1 hESC line from an embryo cultured in 2i
conditions. In conclusion, we demonstrated that FGF/MEK/Erk and GSK3b signaling increases the number of
OCT3/4- and NANOG-positive cells in the human ICM, but does not improve stem cell derivation.
Introduction
In the mouse, blastocyst formation is the result of 2successive differentiation events that are driven by the ac-
tion of the transcription factors OCT3/4, CDX2, NANOG, and
GATA6 [1,2]. The first segregation event starts at the compacted
morula stage and results in 2 distinct lineages, the trophecto-
derm (TE) and the inner cell mass (ICM). Subsequently, there is
a loss of CDX2 in the ICM, resulting in its segregation from the
TE [3–6]. The ICM produces the embryonic cells, extraembry-
onic mesoderm, and primitive endoderm (PE), whereas the TE
becomes a part of the chorion and the placenta [3,5].
The second segregation event allocates the ICM into epi-
blast (EPI) and hypoblast or PE. Initially, the precursor cells of
EPI and PE are mixed within the ICM and express NANOG
andGATA6, respectively [1]. In cow, pig, and human,OCT3/4
expression is not exclusively restricted to the ICM, but is first
coexpressed with CDX2 in the TE [3,7,8]. Berg et al. under-
lined interspecies diversity in the segregation of the first lin-
eages, which is based on evolutionary-conserved divergence
ofOCT3/4 regulation [8]. Therefore, it is clear that the order of
temporal and spatial use of the genetic modules and possibly
signaling networks is distinct in different animals. Im-
portantly, the mechanism and timing of lineage specification
in humans are largely unknown, and few studies have eval-
uated the expression patterns of known key regulators [9–12].
The first successful mouse embryonic stem cell (mESC)
lines were derived from the ICM in 1981 [13,14]. Initially,
mESC derivation was only possible from the 129 strain using
standard optimized culture conditions, while it was less ef-
ficient and mostly unsuccessful in other strains of mice
[13,14]. By using small molecules to inhibit specific signaling
pathways involved in pluripotency, the derivation of naı¨ve
mESC from strains other than the 129 strain became feasible
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as well. Two specific inhibitors, PD0325901 and CHIR99021
(also known as the 2i condition), permitted the derivation of
ESC lines, even from nonpermissive strains like the nonobese
diabetic strain [15] and from rat embryos, resulting in the
first rat ESC lines [16,17]. PD0325901 acts on the fibroblast
growth factor (FGF) pathway by targeting mitogen-activated
protein kinase/extracellular signal-regulated kinase (MAPK/
ERK kinase or MEK), which causes blockade of differentia-
tion [18]. CHIR99021 inhibits glycogen synthase kinase (GSK)
3b, thereby activating the Wnt pathway, which plays an
important role in self-renewal. Other small molecules have
also shown to affect stem cell derivation and support em-
bryonic stem cell self-renewal [19]. For example, a combina-
tion of 3 inhibitors (SU5402 for FGFR, PD184352 for ERK,
and CHIR99021 for GSK3b) supports stem cell derivation and
culture of the mouse strain C57BL/6N, whereas the combi-
nation of LIF, PD98059, and BIO increased the mESC deri-
vation efficiency by 5-fold [20–23].
Interestingly, similar small molecules have recently been
reported to manipulate cell fate during preimplantation de-
velopment. In vitro culture of mouse embryos in the 2i
condition directs the ICM of mouse embryos toward a state
in which all cells are NANOG positive and GATA4 negative,
thus inhibiting hypoblast formation [24]. Yamanaka et al.
confirmed the role of FGF signaling in the segregation of the
PE and EPI in the mouse blastocyst, and stated that the FGF/
MAPK signaling influences the specification of the PE and
EPI lineages in a stochastic and progressive way [25]. Re-
cently, Roode et al. showed that inhibiting FGF and GSK3b
signaling in the 2i condition does not prevent hypoblast
formation in humans [11]; however, only one combination of
small molecules was tested, and the effect on subsequent
stem cell derivation was not investigated.
We have explored the use of both single and combined in-
hibitors on blastocyst development and early lineage restric-
tion in the human. Secondly, we verified the effect of
manipulating cell fate during early embryonic development
on its capacity to derive human embryonic stem cells (hESCs).
These studies in human are necessary to clarify if themolecular
signaling pathways that are involved during first- and second-
lineage commitment in mice are conserved in human. By
studying the differences in timing and underlying molecular
mechanisms, we could obtain some crucial information about
the lineage commitment during early human embryonic de-
velopment and the origin of pluripotent cells in human.
Materials and Methods
Ethical aspects
The Institutional Review Board approval was obtained
from the Ethics Committee, Ghent University Hospital
(2009/281), and the Belgian Federal Ethics Committee on
Embryo Research (Adv-030). All patients donating embryos
for the present study signed informed consents before their
IVF/ICSI cycle.
Embryo source
Fresh, spare embryos that did not meet the IVF laborato-
ry’s cryopreservation criteria after embryo transfer due to
high fragmentation (‡ 25%) on day 2 or day 3 of develop-
ment (day of oocyte retrieval being day 0), multinucleated
blastomeres on day 2, delayed development (< 5 blastomeres
on day 3 or a £ 1 blastomere increase from day 2 to 3), and/
or abnormal fertilization (0, 1, or ‡ 3PN) on day 1 were used
in this study. For inclusion into the study, embryos must
have contained at least 4 blastomeres on day 3 and could not
have had more than 50% fragmentation.
Thawing of 1,2-propanediol-frozen embryos
In addition to these fresh embryos, embryos that had
previously been frozen in 1,2-propanediol (PrOH) were used
as well. These embryos were thawed by exposure to se-
quential thawing solutions: solution 1 contained 1M PrOH
and 0.2M sucrose in Dulbecco’s Phosphate-Buffered Saline
(DPBS), supplemented with 0.5% human serum albumin
(HSA); solution 2 contained 0.5M PrOH and 0.2M sucrose in
DPBS/HSA; solution 3 contained 0.2M sucrose in DPBS/
HSA; and solution 4 contained DPBS/HSA. Straws were
removed from liquid nitrogen and kept at room temperature
for 40 s, followed by 30 s on a 30C warm plate. The embryos
were expelled from the straw and quickly moved to solution
1 for 5min at room temperature, followed by solutions 2, 3,
and 4 each for 5min at room temperature. Finally, the em-
bryos were placed in a fresh drop of solution 4 at 37C for
5min before they were cultured at 6% CO2 and 5% O2.
Embryo scoring and culture
In total, over 1,000 fresh, day-3 spare embryos and 131
frozen embryos cultured from the zygote stage in a Cook
Cleavage medium (Cook Ireland LTD., Limerick, Ireland,
www.cookmedical.com) at 37C, 5% O2, and 6% CO2 were
collected from the IVF lab. After inclusion into the study,
embryos were randomized to 5 different small-molecule
treatment groups based on their number of blastomeres on
day 3 of development. Day-3 embryos were then cultured for
3 more days in the Cook Blastocyst medium (Cook Ireland
LTD., Limerick, Ireland, www.cookmedical.com) supple-
mented with the studied small molecules. Small molecules
used in this study were Parke Davis 0325901 (PD0325901;
Cayman, Ann Arbor, MI; 1 mM), 6-bromoindirubin-3¢-oxime
(BIO; Cayman, 3 mM), and CHIR99021 (CHIR, Axon Med-
chem, 3mM). PD0325901 is an inhibitor of the MEK pathway,
and BIO and CHIR99021 are both inhibitors of the GSK3b
pathway (activation of Wnt pathway), with CHIR99021 be-
ing a more specific GSK3b inhibitor than BIO. Used con-
centrations were based on recent publications in mice [21,32].
Embryos were randomized to the 5 following study groups:
(i) 3mM BIO, (ii) 1mM PD0325901, (iii) 3 mM BIO and 1 mM
PD0325901, (iv) 3 mM CHIR99021 and 1mM PD0325901 (2i),
and (v) control. Embryos were randomized over the different
study groups based on the blastomere number on day 3 of
development, by using QuickCalc’s random number gener-
ator. Embryos were evaluated morphologically on day 4, 5,
and 6 of their development. On day 6 in the afternoon, all
blastocysts were scored at a fixed time interval using the
grading system taken from Stephenson et al. [26]. Under this
scoring system, ICM grades A and B are reserved for large
and distinct ICMs, with grade A being more compact and B
having larger, less-compact cells. Grade C scoring is used for
small ICMs, grade D for degenerating ICMs, and grade E
when no apparent ICM is visible. For this study, grades A
EFFECT OF 2I ON THE HUMAN EMBRYO 297
and B were considered good-quality ICMs, while C, D, and E
were considered poor-quality ICMs. TE grades of A, B, or C
correspond to good, moderate, or poor quality, respectively.
Blastocyst expansion was graded from 1 (no expansion of
overall size) to 6 (fully hatched from zona pellucida). After
scoring, the blastocysts were either used for immunostaining
or hESC derivation purposes.
Additional 30 embryos were cultured in the Cook Blas-
tocyst medium from day 3 until day 7 of embryonic devel-
opment, to determine the differences in NANOG and
GATA6 expression between day-6 and day-7 blastocysts.
Immunocytochemistry
Blastocysts were fixed in 4% paraformaldehyde in phos-
phate-buffered saline (PBS) for 20min (room temperature) or
overnight (4C). They were rinsed in PBS and stored in PBS
(4C) until staining. At that point, blastocysts were permea-
bilized in 1·PBS + 0.1% Triton X-100 for 10min, moved to
PBS + 0.5% Triton X-100 for 20min, rinsed in PBS shortly,
and eventually blocked overnight in PBS + 0.05% Tween-
20 + 1% bovine serum albumin (blocking solution). Primary
antibodies applied were OCT3/4 (1:200, SC-8628; Santa Cruz
Biotechnology Inc., Heidelberg, Germany), NANOG (1:200,
AF1997; R&D Systems, Oxon, United Kingdom), and
GATA6 (1:200, SC-9055; Santa Cruz Biotechnology Inc.).
Blastocysts were treated with primary antibodies in the
blocking solution for 48 h at 4C. After this incubation, em-
bryos were rinsed in 1 ·PBS and treated with secondary
antibodies in the blocking solution for 48 h at 4C. Secondary
antibodies used were donkey anti-goat-FITC (1:200, 705-095-
147; Bioconnect, Huissen, The Netherlands) and donkey anti-
rabbit-CY3 (1:2000; 711-165-152; Bioconnect). Blastocysts
were rinsed again and mounted on glass slides in small
drops of Vectashield containing 4¢,6-diamidino-2-pheny-
lindole (DAPI; Vector Laboratories Ltd., Peterborough, Uni-
ted Kingdom). Positive ICM cell numbers were counted
under a fluorescence microscope (Olympus 1 · 71; Olympus,
Aartselaar, Belgium) equipped with filters for DAPI
(377 nm), FITC (485 nm), and Cy3 (560 nm). Cells that were
not positive for OCT3/4, NANOG, or GATA6 were consid-
ered TE. Stem cells were used as positive controls, whereas
blastocysts incubated with an antibody diluent, without the
primary antibody, were used as negative controls.
hESC derivation
The protocol used for embryonic stem cell derivation in
our lab was recently reported by O’Leary et al. [27,28].
Briefly, day-6 (D6) blastocysts with good- and poor-quality
ICMs were exposed to warmed Acidic Tyrode’s (Sigma,
Bornem, Belgium, T1788) to remove their zona pellucida.
After washing, the blastocyst was transferred to individual
culture dishes with a nearly confluent feeder layer of mito-
mycin-C- (Sigma, M4287) treated CD1 mouse embryonic fi-
broblasts (MEFs). The culture environment from the
blastocyst stage to hESCs consisted of 37C, 6% CO2, and 5%
O2 in a standard hESC culture medium consisting of the
knockout Dulbecco’s modified Eagle medium (KO-DMEM;
Invitrogen, Merelbeke, Belgium, 10829-018), supplemented
with 20% knockout serum replacement (KO-SR; Invitrogen,
10828-028), 1% non-essential amino acids (NEAA; Invitro-
gen, 11140-035), 0.1mM l-glutamine (Invitrogen, 25030-024),
1% penicillin/streptomycin (Invitrogen, 15140-122), 0.1mM
beta-mercaptoethanol (Sigma, M3148), and 4 ng/mL basic
fibroblast growth factor (bFGF; Invitrogen, 13256-029). Ob-
servation and refreshment were done daily to observe areas
of presumed ICM-derived cells (post-ICM intermediates or
PICMIs [28]) or emerging colonies. Once hESC outgrowths
emerged, they were mechanically passaged until numerous
stable colonies could safely be transferred to a tissue culture
flask. The hESC-populated flasks were expanded with 1mg/
mL collagenase type IV (Invitrogen, 17104-019) every 5 to 6
days with daily medium refreshment.
Alkaline phosphatase live staining
The alkaline phosphatase (AP) live staining was per-
formed using 1 ·AP Live Stain working solution, by diluting
the 500· stock solution (Invitrogen, A14353) in DMEM/F-12
(Invitrogen, 10565-018). Stem cells were first rinsed with
prewarmed DMEM/F-12 and then incubated with the 1·
AP working solution for 30min. At this point, the AP live
stain was removed, and cells were washed again twice with
DMEM/F-12 for 5min per wash. After the fresh DMEM/F-
12 medium was added, pictures could be captured within
30–90min of staining. After visualization, DMEM/F-12
could be replaced with a fresh hESC medium, and the cells
could be maintained in culture.
Karyotyping of hESC lines
Nearly confluent culture flasks of hESCs at early passages
were induced to metaphase by colcemide (1:100 in salt solution;
Karyomax, Invitrogen, 15210-057), harvested with 0.25% tryp-
sin–EDTA (Invitrogen, 25200-056), treated with a hypotonic
solution of HCL (Sigma, T-3038), and fixed in a 1:3 methanol/
acetic acid solution (Merck, Overijse, Belgium, 1.06009.1000;
Sigma, A 6283). The metaphase spreads were then prepared
and analyzed as described previously using the G-banding
technique [29]. For karyotyping, 10 numerical metaphase
spreads and 3 complete karyograms were analyzed.
Cryopreservation of hESC lines
Before freezing, colonies of hESCs were treated with
10 mM Y27632 (ROCK inhibitor, ROCKi) for 1 h, after which
enzymatic passaging with 1mg/mL collagenase type IV
(Invitrogen, 17104-019) was carried out. When the cell pellet
was collected, 2mL precooled freezing medium (90% hESC
medium with ROCKi and 10% DMSO) was added, and the
cells were stored in a cryofreezing container (Nalgene, Ros-
kilde, Denmark, 5100-0001) at - 80C. Later on, cryovials
were thawed in a 37C warm water bath, and the cells were
added to 10mL hESC medium plus ROCKi. After centrifu-
gation, the supernatants were removed, and the pellet was
resuspended in 1mL medium with ROCKi. This cell sus-
pension was then cultured in a tissue flask covered with
MEFs, and 2 days later, after the first culture refreshment
with standard hESC medium, cells were refreshed daily.
Statistical analysis
Developmental data were analyzed by contingency table
analysis followed by Chi-square or Fisher’s exact tests where
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appropriate. P-values of £ 0.05 were considered to be sig-
nificant. Parameters of blastocyst quality were compared
using one-way analysis of variance followed by Tukey post-
test when the level of significance reached P < 0.05.
Results
Impact on blastocyst formation and quality
Blastocyst rates of embryos cultured in the presence of
PD0325901 and CHIR99021, PD0325901 and BIO, and
PD0325901 tended to be higher than the control group, but
not statistically different. Embryos cultured in the presence
of BIO alone showed similar blastocyst formation (31.1%) as
the control embryos (Table 1, 38.9%, 36.8%, and 36.7% vs.
29.8%, respectively; P = 0.18, P = 0.14, and P = 0.11, respec-
tively; and 31.1% vs. 29.8%, respectively). A and B ICMs
were considered as good-quality ICMs, whereas C, D, and E
ICMs were considered as poor-quality ICMs. The control
group and most of the different small-molecule groups
contained equal amounts of good- and poor-quality ICMs
(Table 1). In the BIO group, 63.5% of the blastocysts had a
good-quality ICM (compared to the control group, P = 0.06).
After scoring the TE, no significant differences in formation
and quality were observed between the different small-
molecule groups and the control.
2i stimulates the number of OCT3/4 single-positive
cells in human blastocysts
To compare the influence of the MEK and GSK3b inhibi-
tors on lineage segregation, embryos were cultured from day
3 to day 6 in presence of different inhibitors of these path-
ways, alone and in combination. Blastocysts were im-
munostained to enquire GATA6 and OCT3/4 expression. Both
single and double expression of these markers was observed.
As we observed a predominant expression of the lineage
markers OCT3/4 and GATA6 in the presumptive ICM clump,
only these positive ICM cells were counted for analyzing the
effect of the small molecules on second lineage segregation in
the following experiments. Both single- and double-positive
cells were observed in the ICM, but only the single-positive
cells were included in our analysis. Combined expression of
both GATA6 and OCT3/4 is suggesting a future hypoblast fate.
In blastocysts with both good- (grades A and B) and poor-
quality ICMs (grades C and D), there was a significant increase
in OCT3/4 single-positive cells in the 2i group compared to the
control and all other treatment groups (aside from PD0325901
in good-quality blastocysts). There was no difference in the
number of GATA6 single- or double-positive cells. Embryos
cultured in the presence of BIO and PD0325901, alone or in
combination, did not show more OCT3/4- or GATA6 single-
positive cells compared to the control group. Blastocysts with
poor-quality ICMs in the BIO & PD0325901 group showed
significantly fewer OCT3/4 single-positive cells compared to
their control (Table 2, Fig. 1a).
Nanog expression increases after
FGF/MEK/Erk inhibition
As the initial blastocyst stainings showed that the number of
OCT3/4 single-positive cells was significantly higher in the 2i
group, we wanted to check if there were also more NANOG-
Table 1. Overall, A/B-, and C/D/E-Quality Inner Cell Mass Blastocyst
Formation Efficiency in Different Small-Molecule Groups
Experimental group Development to blastocysts (%) Type A/B (%) Type C/D/E (%)
Control (n= 469) 29.8 (n= 140) 52.9 (n = 74) 47.1 (n= 66)
BIO (n = 167) 31.1 (n= 52) 63.5 (n = 33) 36.5 (n= 19)
PD0325901 (n = 177) 36.7 (n= 65) 48.0 (n = 31) 52.0 (n= 34)
BIO +PD0325901 (n = 133) 36.8 (n= 49) 44.9 (n = 22) 55.1 (n= 27)
CHIR +PD0325901 (n= 59) 38.9 (n= 23) 52.2 (n = 12) 47.8 (n= 11)
Table 2. Mean Numbers of OCT3/4-, GATA6-, and Double-Positive Inner Cell Mass Cells in Blastocysts
with A/B- and C/D-Quality Inner Cell Mass in Different Small-Molecule Groups
OCT3/4 alone GATA6 alone Dp ICM
A- & B-quality ICM
Control (n= 10) 5.10 – 4.48 6.10 – 4.82 6.20 – 10.79 17.40– 10.36
BIO (n = 14) 6.43 – 5.80 5.71 – 4.94 2.21 – 4.06 14.36– 6.15
PD0325901 (n= 7) 9.43 – 6.83 3.29 – 3.77 4.57 – 5.16 17.29– 8.83
BIO & PD0325901 (n= 5) 6.40 – 4.62 6.00 – 5.70 1.80 – 4.02 14.20– 7.01
CHIR & PD0325901 (n = 6) 14.17– 5.78a 7.83 – 6.37 1.00 – 2.00 23.00– 13.10
C- & D-quality ICM
Control (n= 9) 4.11 – 2.98 4.22 – 4.44 4.56 – 8.76 12.89– 5.51
BIO (n = 3) 1.67 – 1.53 8.67 – 8.33 3.00 – 2.56 13.33– 6.81
PD0325901 (n= 4) 3.75 – 2.87 7.25 – 3.69 0.50 – 1.00 11.50– 3.32
BIO & PD0325901 (n= 7) 0.86 – 2.27b 2.29 – 3.30 7.67 – 3.69 10.71– 5.50
CHIR & PD0325901 (n = 6) 13.00– 7.72a 5.50 – 5.21 2.50 – 3.73 21.00– 7.16b
Statistic significances compared to control: aP< 0.01; bP < 0.05.
Mean– standard deviation.
Dp, number of double-positive cells for OCT3/4 and GATA6; ICM, number of inner cell mass cells.
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positive cells in those blastocysts. NANOG is, together with
OCT3/4, one of the most important pluripotency markers for
subsequent stem cell derivation purposes. In addition, it is
accepted to be a more specific marker for the EPI, whereas
OCT3/4 is a more general ICM marker [10,30]. By performing
these additional stainings in the PD0325901 and 2i group, we
wanted to check if the observed increase in OCT3/4-positive
cells is accompanied with a shift toward more EPI cells in the
ICM during the second lineage segregation. Again, double-
positive cells were not included for analysis.
Overall, we observed that NANOG and GATA6 were ex-
pressed in a mutually exclusive way in the cells of the ICM,
with cells being either positive for NANOG or for GATA6,
with few exceptions in the control group, where some cells
were double positive. In the blastocysts with good-quality
ICMs, we observed significantly more NANOG-positive cells
after culturing in the presence of PD0325901 alone and also
more NANOG-positive cells in the 2i group. As we observed
before, no effect on the number of GATA6-positive cells
could be found. In blastocysts with poor-quality ICMs, the
number of NANOG-positive cells did not increase after MEK
inhibition, neither alone nor in combination with GSK3b
inhibition. In these blastocysts, a trend toward less GATA6-
positive cells could be observed in the 2i group, but this was
not significant (P = 0.06) (Table 3 and Fig. 1b).
ICM cell number tends to increase after 2i treatment
During the immunofluorescent analysis of the blastocysts,
we also estimated the number of ICM cells based on cell
FIG. 1. (a) Immunofluore-
scent staining for OCT3/4
and GATA6 and a merged
image with 4¢,6-diamidino-2-
phenylindole (DAPI) of day-6
blastocyst in the control (A),
PD0325901 (B), and 2i (C)
group. Note the difference in
number of OCT3/4-positive
inner cell mass (ICM) cells in
the PD0325901 and 2i blas-
tocysts compared to the con-
trol. Scale bar, 100mm. (b)
Immunofluorescent staining
for NANOG and GATA6 and
a merged image with DAPI
of day-6 blastocyst in the
control (D) and 2i (E) group.
Note the difference in
number of NANOG-positive
ICM, cells in the 2i blasto-
cyst compared to the control.
Scale bar, 100mm.
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location. This showed an increase in the ICM cell number in
the 2i group compared to the control group, when looking at
the OCT3/4-stained blastocysts. This increase was significant
in the poor-quality blastocysts (21.00 – 7.16 vs. 12.89– 5.51,
P < 0.05), but not in the good-quality blastocyst group
(23.00 – 13.10 vs. 17.40– 10.36) (see Tables 2 and 3).
Blastocyst culture until day 7
To check whether the expression of NANOG and GATA6
changes in blastocysts from day 6 to day 7, we cultured some
additional blastocysts until day 7 of embryonic development,
and stained these for the EPI marker NANOG and the hy-
poblast marker GATA6. We observed a significant decrease
in the number of NANOG-positive cells (P < 0.05) and a
trend toward less GATA6-positive cells (P= 0.07) compared
to day-6 blastocysts (Table 4).
Stem cell derivation
As we observed a higher number of pluripotent OCT3/4-
and NANOG-positive cells after embryo culture in the
presence of the small-molecule inhibitors PD0325901 and
CHIR99021, we verified if subsequent derivation of hESCs
could be performed.
After initial embryo culture in presence or absence of the 2
inhibitors, day-6 blastocysts with both good- and poor-
quality ICMs were plated in a standard hESC medium on
MEFs (13 control blastocysts: 7 with good-quality ICMs and
6 with poor-quality ICMs; 20 2i blastocysts: 10 with good-
quality ICMs and 10 with poor-quality ICMs). Of the plated
control blastocysts, 23% formed PICMIs [34], and 15.4%
formed embryonic stem cell colonies. This resulted in the
derivation of 2 new hESC lines in standard conditions
(UGent11-1 and UGent11-2; Table 5 and Fig. 2). Of the 20
plated 2i blastocysts, 1 (5%) initial outgrowth was formed,
which resulted in a new embryonic stem cell line (UGent11-3;
Table 5 and Fig. 2). From these results, no differences in the
derivation efficiency between the groups can be deduced. All
3 established lines originated from blastocysts with an A/B
quality ICM. Their pluripotent status was confirmed by im-
munostaining for OCT3/4 and NANOG, and they were
cultured for at least 30 passages. Similar to undifferentiated
pluripotent cultures of previously established hESC lines, all
our cell lines possessed high levels of AP activity. Karyotype
analysis revealed that all lines had a normal karyotype
(Table 6 and Fig. 3). The cells could be cryopreserved with-
out any effect on their ability to re-establish pluripotent hESC
colonies. We must remark that the hESC line originating
from the 2i blastocyst showed lower survival after passaging
and lower self-renewal capacity. This problem could how-
ever be solved by passaging this line in the presence of the
ROCK inhibitor Y27632 (10mM), which has shown to have a
positive effect on cell survival [31]. Interestingly, this line is a
sibling from one of the control lines, which means that both
lines are derived from sibling embryos that were cultured in
different conditions (control and 2i). Additional experiments,
plating 2i embryos in a 2i-supplemented medium, elucidated
the absence of successful hESC derivation in these conditions
(Table 5).
Discussion
In the past, differences in lineage segregation between
different species have been reported, based on evolutionary
divergence of OCT3/4 regulation [3,7,8]. More specifically,
changes in Cdx2:Oct4 ratios and the relative timing of TE
commitment are observed. However, the mechanism of lin-
eage segregation in humans has only been studied by a few
groups [9,10,12,32].
In the present study, early lineage segregation was eval-
uated at one fixed time point on day 6 of development. The
exact timing of OCT3/4 restriction to the ICM is however
still not clear. We observed the human ICM to have cells
expressing OCT3/4, NANOG, and GATA6. Only cells without
coexpression of these genes were taken into account for an-
alyzing the effect of the small molecules on second lineage
segregation. Some blastocysts showed expression of NANOG
or OCT3/4 in a few TE cells as well, but this was only seen in
a very small minority of the early blastocysts. As such, our
Table 3. Mean Numbers of NANOG-, GATA6-, and Double-Positive Inner Cell Mass Cells in Blastocysts
with A/B- and C/D-Quality Inner Cell Mass in Different Small-Molecule Groups
NANOG alone GATA6 alone Dp ICM
A- & B-quality ICM
control (n= 6) 7.67 – 4.59 4.50 – 3.67 3.33 – 3.44 15.5 – 8.96
PD0325901 (n= 14) 15.00 – 7.30a 7.00 – 4.74 0.00 22.00– 10.36
CHIR & PD0325901 (n = 11) 14.27 – 8.66a 5.55 – 5.26 0.00 19.82– 11.75
C- & D-quality ICM
control (n= 8) 5.75 – 3.54 9.00 – 5.18 0.63 – 0.92 13.67– 7.13
PD0325901 (n= 11) 6.27 – 2.90 5.00 – 5.83 0.00 11.27– 5.22
CHIR & PD0325901 (n = 4) 5.75 – 1.71 3.25 – 2.22 0.00 9.00 – 3.56
Statistic significances compared to control: aP< 0.05.
Mean– standard deviation.
Dp, number of double-positive cells for NANOG and GATA6s.
Table 4. Mean Numbers of NANOG-Alone
and GATA6-Alone Positive Inner Cell Mass Cells
NANOG alone GATA6 alone
Day 6 (n = 14) 8.36 – 4.98 8.50 – 5.37
Day 7 (n = 7) 3.57 – 3.60a 4.00 – 4.20
Statistic significances compared to control: aP< 0.05.
Mean– standard deviation.
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results are in agreement with those of Chen et al., where
OCT3/4 expression was also predominantly detected in the
ICM, but not with the results of Cauffman et al. We did not
see any differences in the number of OCT3/4-positive cells
according to the expansion stage of the blastocyst (data not
shown). This sustains the suggestion that the first segrega-
tion event in human takes place at day 6 of development.
In mice, the FGF-signaling pathway plays an important
role in the segregation of the hypoblast and EPI from the
ICM. It was demonstrated that by modulation of the FGF
pathway, the fate of the ICM cells to become hypoblast or
EPI can be altered [24,25]. Inhibition of the FGF/MAPK
pathway led to a reallocation of the ICM cells toward EPI
and an inhibition of hypoblast formation [25]. In contrast,
addition of exogenous FGF shifted the balance toward more
hypoblast cells [30]. It seems that FGF/ERK signaling is
crucial in the formation of the hypoblast, and altered sig-
naling can lead to defective hypoblast formation, as the lin-
eage segregation of hypoblast and EPI requires the activation
of the receptor tyrosine kinase (RTK)-Ras-MAPK signaling
pathway [1]. Recently, Roode et al. published that human
hypoblast formation is not dependent on FGF signaling [11].
Table 5. Overview of the Postinner Cell Mass-Intermediate Formation and Human Embryonic
Stem Cell Derivation Rates of Control and 2i Blastocysts in Standard
or 2i-Supplemented Human Embryonic Stem Cell Medium
PICMI
formation
hESC derivation
(% of attached blastocysts)
hESC derivation
(% of PICMIs cultured)
Control in standard hESC medium 23.0% (3/13) 15.3% (2/13) 66.6% (2/3)
2i in standard hESC medium 5.0% (1/20) 5.0% (1/20) 100% (1/1)
2i in 2i supplemented hESC medium 0% (0/16) 0% (0/16) 0% (0/0)
PICMI, post-ICM-intermediate; hESC, human embryonic stem cell.
FIG. 2. (a) Bright-field pic-
tures of the early stages in
human embryonic stem cell
(hESC) derivation. (A) Con-
trol hESC line G11-1: day 6
postplating the blastocyst
and day 2 postcutting the
area of interest; (B) Control
hESC line G11-2: day 2 and 4
postcutting the area of inter-
est after plating the day-6
control blastocyst; (C) hESC
line G11-3 (embryo culture in
2i): day 2 postcutting the area
of interest after plating the
day-6 control blastocyst and
established hESC colony after
2nd cutting. Scale bar, 100mm.
(b) Immunofluorescent stain-
ing of all derived hESC lines
for OCT3/4 and NANOG. (D)
Control hESC line G11-1; (E)
control hESC line G11-2; (F)
hESC line G11-3 (embryo cul-
ture in 2i). Scale bar, 50mm.
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They observed no reduction of GATA4-positive cells upon
inhibition of FGF/Erk signaling, but there were also no ef-
fects on the NANOG-positive cell population. Our study
confirms that FGF/MEK/Erk inhibition does not prevent the
formation of GATA6-positive cells, but we did observe an
increase in the number of OCT3/4- and NANOG-positive
cells in the ICM upon 2i treatment. The increase in OCT3/4-
or NANOG-positive cells may have occurred by 3 distinct
mechanisms: (i) an increase of EPI cell proliferation; (ii) an
upregulation of OCT4 and NANOG in the pre-EPI cells, or (iii)
acceleration in the differentiation of the blastomeres to EPI.
Comparison of the ICM cell numbers in the different treat-
ment groups suggested that this increase is probably caused
by an increase in EPI proliferation in the 2i culture condition.
In the article of Roode et al. [11], GATA6-positive cells
were distributed throughout the whole blastocyst. We did
not observe GATA6 expression in the TE cells (except for
some early blastocysts, but due to its rarity, we only focused
on the expression of GATA6 inside the ICM). The observed
difference in GATA6 expression between the experiments of
Roode et al. and the ones presented here could however be
the result of a distinct antibody specificity, as both experi-
ments applied different GATA6 antibodies. Our experiments
differ from the previous, because we used over 1,000 human
spare embryos to analyze the effect of both single and double
inhibition of FGF/MEK/Erk and GSK3b on the ICM quality
of D6 blastocysts, and we stained 125 blastocysts with early
lineage segregation markers. The number of human embryos
used by Roode et al. was not mentioned. Importantly, we
also performed a separate analysis for blastocysts of both
good- and poor-quality ICMs.
Our results show that also in humans, inhibition of the
FGF/MEK/Erk and GSK3b pathway (2i condition) leads to a
significant increase in OCT3/4- and NANOG-positive cells
in the blastocysts of good quality, while the ones of poor
quality showed more OCT3/4-positive cells and similar
amounts of NANOG-positive cells. Interestingly, hypoblast
formation was not prevented during second lineage segre-
gation in human, which reveals still important differences
between human and mouse. These differences might explain
the inability of obtaining hESCs from the embryo level on-
ward in human using the 2i condition. Another explanation
for that might be the used culture medium, as the 2i condi-
tion is known to maintain the culture of naı¨ve ESCs, a culture
medium that is supplemented with LIF might be more
supportive.
Since the availability of human spare embryos is much
lower compared to animal models, we did not do any dose
finding, but used small-molecule concentrations that were
reported before in mouse studies. It is possible, however, that
other doses are needed to obtain similar effects in humans as
in mice. In this study, both BIO and CHIR99021 were used as
GSK3b inhibitors, and it is known that CHIR99021 is a more
specific GSK3b inhibitor [33]. From our results, we could not
observe an increase in the number of pluripotent EPI cells in
the ICM by the addition of BIO, alone or combined with
PD0325901. This will probably result from the nonspecificity
of BIO, as the combination CHIR99021-PD0325901 was more
effective in increasing pluripotency.
Staining of human blastocysts at day 7 of development
showed a decrease in the number of NANOG-positive cells
(P < 0.05) and a trend toward less GATA6-positive cells
(P = 0.07) compared to D6 blastocysts. As standard culture in
Table 6. Overview of the Number of Counted,
Analyzed, and Normal Metaphases
of Each Human Embryonic Stem Cell Line,
Using the G-Banding Technique
Cell line
Number
of counted
metaphases
Number
of analyzed
metaphases
Percentage
of normal
metaphases
Control line G11-1 10 3 100%
Control line G11-2 10 3 100%
2i line G11-3 10 3 100%
FIG. 3. Example of G-band-
ing, showing a normal karyo-
gram in all lines.
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the Cook Blastocyst medium is only reported until day 5/6
of development, it is possible that our culture environment
was suboptimal for supporting embryonic development
until day 7. The observation that the blastocyst quality de-
creased from day 6 to 7 substantiates this suggestion.
As we were able to increase the number of OCT3/4- and
NANOG-positive cells by inhibition of FGF and GSK3b
signaling, we wanted to verify if there was any effect on the
capability of these embryos to derive hESCs. In mice, the
derivation efficiency in standard culture systems is very low
[34]. However, it has been shown that the addition of dif-
ferent factors to the culture medium (LIF, PD98059, and BIO)
can lead to a 5-fold increase in mESC derivation rates [20]. In
human, we observed an hESC derivation efficiency of 15.4%
in the control group, and of 5% in the 2i condition. The low
number of cell lines generated, however, did not allow any
conclusion to be drawn regarding the efficiency of derivation.
From literature, it is sometimes difficult to compare efficien-
cies on hESC derivation, since information about the origin,
number, and quality of embryos that were used and the
number and quality of plated blastocysts is not always de-
scribed in reports. Stro¨m et al. showed a derivation efficiency
of 12.8% using fresh spare embryos (30 permanent lines/234
blastocysts) [35]. In a comparable study from our group, we
obtained a similar efficiency of stem cell derivation using a
higher number of embryos compared to our present study:
12.1%, 16 permanent lines on 132 plated blastocysts [27]. In-
terestingly, embryos resulting in a successful hESC line orig-
inated from a patient cycle in which a successful pregnancy
was established. This reflects the overall health of a cohort of
embryos within a patient, which has recently been shown to
affect the hESC derivation efficiency [26].
All hESC lines were derived from blastocysts with good-
quality ICMs, which contained more OCT3/4- and NANOG-
positive cells. Previously, we showed that good-quality ICMs
originating from embryos with multiple poor-quality traits
are unable to generate hESC lines, in contrast to good-quality
ICMs from embryos with only a single poor-quality trait [27].
In the current study, there was no difference in the number
of poor-quality traits of day-3 embryos between the groups
that could have influenced stem cell derivation efficiency.
Also, the maternal age and blastomere number on day 3 did
not differ between the groups, confirming the proper ran-
domization of the embryos.
The initial slow growth of the created 2i line (UGent11-3)
could be due to the presence of the FGF inhibitor PD0325901
in the culture medium, as it is known that hESCs rely on the
FGF pathway for their sustained self-renewal and plur-
ipotency. Also, it needs to be taken into account that the used
culture conditions for hESC derivation were similar between
the different groups, as this study was based on standard
hESC culture. Aiming toward derivation of naı¨ve hESCs
would require other culture conditions, such as the use of the
N2B27 medium supplemented with 2i and LIF lacking bFGF,
but this was beyond the scope of the present article. Hanna et
al. succeeded in transforming existing hESC into naı¨ve
hESCs by transfection of the cells with Oct4 and Klf4 or Klf4
and Klf2 in the presence of PD0325901, CHIR99021, LIF, and
the Klf4/Flf2 regulator forskolin [37]. These inhibitors have
also been used to derive naı¨ve pig stem cells from the ICM,
combined with transfection of KLF2 or KLF4 and OCT3/4
[38]. Therefore, additional experiments based on the use of 2i
condition during derivation might lead toward naı¨ve hESCs
from the blastocyst stage onward.
Recently, we identified an intermediate stage between the
ICM and eventual hESC colony, which we called post-ICM
intermediate (PICMI), and which contains a unique signature
compromising both early- and late-EPI markers [28]. This
finding supports the evidence that existing hESCs are more
similar to mouse EPI stem cells (mEpiSC) than to mESCs,
which are derived from the ICM. By using a derivation
medium that contains the perfect cocktail of small molecules
and growth factors, it should be possible to increase the
derivation rates in the human, and to push the cells toward a
more naı¨ve state. The derivation of naı¨ve hESCs could open
new windows for patient-specific clinical applications and
disease-relevant research [37].
Conclusion
To our knowledge, this is the first report showing that
the combination of inhibitors of FGF/MEK/Erk and GSK3B
signaling increases the number of OCT3/4- and NANOG-
positive cells in the human ICM, but does not improve stem
cell derivation. We observed significantly more OCT3/4-
positive cells in all blastocysts and also more NANOG-posi-
tive cells in blastocysts with good-quality ICMs after using
the 2i condition. There were no significant differences in
numbers of GATA6-positive cells. Also, we succeeded in the
derivation of 3 different hESC lines from D6 blastocysts, with
1 line coming from an embryo that was cultured in the 2i
condition. Interestingly, 2 of the derived stem cell lines are
sibling lines, derived from sibling embryos that were cultured
in different conditions. Our future research will focus on the
use of different kinds of small-molecule-supplemented deri-
vation media, which could hopefully lead to higher deriva-
tion rates of a new type of naı¨ve hESCs.
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